ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Circulating Tumour DNA (ctDNA) Testing Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-30E15259
Home | Market Reports | Science| Biological Sciences
Global Circulating Tumour DNA ctDNA Testing Market Research Report 2023
BUY CHAPTERS

Global Circulating Tumour DNA (ctDNA) Testing Market Research Report 2025

Code: QYRE-Auto-30E15259
Report
May 2025
Pages:100
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Roche
Illumina Inc
Sysmex Corporation
Bio Rad
Biocartis
Qiagen NV
GuardantHealth
GSK
Astrazeneca plc
Neogenomics Laboratories
Amoydx
Annoroad
Burning Rock Biotech
Nexomics
ORIOMICS
Signatera

Circulating Tumour DNA (ctDNA) Testing Market

The global market for Circulating Tumour DNA (ctDNA) Testing was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Circulating tumor DNA (ctDNA) is found in the bloodstream and refers to DNA that comes from cancerous cells and tumors. Most DNA is inside a cell’s nucleus. As a tumor grows, cells die and are replaced by new ones. The dead cells get broken down and their contents, including DNA, are released into the bloodstream. ctDNA are small pieces of DNA, usually comprising fewer than 200 building blocks (nucleotides) in length.The quantity of ctDNA varies among individuals and depends on the type of tumor, its location, and for cancerous tumors, the cancer stage.Circulating-tumor DNA (ctDNA) refers to fragments of DNA derived from tumor cells and circulating in the blood together with cell-free DNA from other sources. Circulating tumor DNA (ctDNA) analyses are minimally invasive and accessible for risk stratification or treatment response monitoring of cancer patients. Compared to tumor biopsy analysis, they are not only less invasive, but also provide a more representative picture, allowing capturing both tumor heterogeneity and multiple tumor sites.
North American market for Circulating Tumour DNA (ctDNA) Testing is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Circulating Tumour DNA (ctDNA) Testing is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Circulating Tumour DNA (ctDNA) Testing in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Circulating Tumour DNA (ctDNA) Testing include Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis, QIAGEN, GuardantHealth, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Circulating Tumour DNA (ctDNA) Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumour DNA (ctDNA) Testing.
The Circulating Tumour DNA (ctDNA) Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Circulating Tumour DNA (ctDNA) Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Circulating Tumour DNA (ctDNA) Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Circulating Tumour DNA (ctDNA) Testing Market Report

Report Metric Details
Report Name Circulating Tumour DNA (ctDNA) Testing Market
Segment by Type
Segment by Application
  • Hospital
  • Medical Center
  • Laboratory
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis, QIAGEN, GuardantHealth, GSK plc, AstraZeneca, NeoGenomics Laboratories, AmoyDx, Annoroad, Burning Rock Biotech
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Circulating Tumour DNA (ctDNA) Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Circulating Tumour DNA (ctDNA) Testing Market report?

Ans: The main players in the Circulating Tumour DNA (ctDNA) Testing Market are Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis, QIAGEN, GuardantHealth, GSK plc, AstraZeneca, NeoGenomics Laboratories, AmoyDx, Annoroad, Burning Rock Biotech

What are the Application segmentation covered in the Circulating Tumour DNA (ctDNA) Testing Market report?

Ans: The Applications covered in the Circulating Tumour DNA (ctDNA) Testing Market report are Hospital, Medical Center, Laboratory

What are the Type segmentation covered in the Circulating Tumour DNA (ctDNA) Testing Market report?

Ans: The Types covered in the Circulating Tumour DNA (ctDNA) Testing Market report are Gastric Cancer Methylation Screening, Esophageal Cancer Methylation Screening, Colorectal Cancer Methylation Screening, Lung Cancer Methylation Screening, Liver Cancer Methylation Screening, Other Cancer Screening

Recommended Reports

Tumor DNA Diagnostics

Cancer Screening & Testing

Molecular & Liquid Biopsy

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Circulating Tumour DNA (ctDNA) Testing Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Gastric Cancer Methylation Screening
1.2.3 Esophageal Cancer Methylation Screening
1.2.4 Colorectal Cancer Methylation Screening
1.2.5 Lung Cancer Methylation Screening
1.2.6 Liver Cancer Methylation Screening
1.2.7 Other Cancer Screening
1.3 Market by Application
1.3.1 Global Circulating Tumour DNA (ctDNA) Testing Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Medical Center
1.3.4 Laboratory
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Circulating Tumour DNA (ctDNA) Testing Market Perspective (2020-2031)
2.2 Global Circulating Tumour DNA (ctDNA) Testing Growth Trends by Region
2.2.1 Global Circulating Tumour DNA (ctDNA) Testing Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Circulating Tumour DNA (ctDNA) Testing Historic Market Size by Region (2020-2025)
2.2.3 Circulating Tumour DNA (ctDNA) Testing Forecasted Market Size by Region (2026-2031)
2.3 Circulating Tumour DNA (ctDNA) Testing Market Dynamics
2.3.1 Circulating Tumour DNA (ctDNA) Testing Industry Trends
2.3.2 Circulating Tumour DNA (ctDNA) Testing Market Drivers
2.3.3 Circulating Tumour DNA (ctDNA) Testing Market Challenges
2.3.4 Circulating Tumour DNA (ctDNA) Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Circulating Tumour DNA (ctDNA) Testing Players by Revenue
3.1.1 Global Top Circulating Tumour DNA (ctDNA) Testing Players by Revenue (2020-2025)
3.1.2 Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Players (2020-2025)
3.2 Global Circulating Tumour DNA (ctDNA) Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Circulating Tumour DNA (ctDNA) Testing Revenue
3.4 Global Circulating Tumour DNA (ctDNA) Testing Market Concentration Ratio
3.4.1 Global Circulating Tumour DNA (ctDNA) Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Circulating Tumour DNA (ctDNA) Testing Revenue in 2024
3.5 Global Key Players of Circulating Tumour DNA (ctDNA) Testing Head office and Area Served
3.6 Global Key Players of Circulating Tumour DNA (ctDNA) Testing, Product and Application
3.7 Global Key Players of Circulating Tumour DNA (ctDNA) Testing, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Circulating Tumour DNA (ctDNA) Testing Breakdown Data by Type
4.1 Global Circulating Tumour DNA (ctDNA) Testing Historic Market Size by Type (2020-2025)
4.2 Global Circulating Tumour DNA (ctDNA) Testing Forecasted Market Size by Type (2026-2031)
5 Circulating Tumour DNA (ctDNA) Testing Breakdown Data by Application
5.1 Global Circulating Tumour DNA (ctDNA) Testing Historic Market Size by Application (2020-2025)
5.2 Global Circulating Tumour DNA (ctDNA) Testing Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Circulating Tumour DNA (ctDNA) Testing Market Size (2020-2031)
6.2 North America Circulating Tumour DNA (ctDNA) Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2020-2025)
6.4 North America Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Circulating Tumour DNA (ctDNA) Testing Market Size (2020-2031)
7.2 Europe Circulating Tumour DNA (ctDNA) Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2020-2025)
7.4 Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumour DNA (ctDNA) Testing Market Size (2020-2031)
8.2 Asia-Pacific Circulating Tumour DNA (ctDNA) Testing Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2020-2025)
8.4 Asia-Pacific Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Circulating Tumour DNA (ctDNA) Testing Market Size (2020-2031)
9.2 Latin America Circulating Tumour DNA (ctDNA) Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2020-2025)
9.4 Latin America Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size (2020-2031)
10.2 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2020-2025)
10.4 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Nexomics
11.1.1 Nexomics Company Details
11.1.2 Nexomics Business Overview
11.1.3 Nexomics Circulating Tumour DNA (ctDNA) Testing Introduction
11.1.4 Nexomics Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
11.1.5 Nexomics Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Circulating Tumour DNA (ctDNA) Testing Introduction
11.2.4 Roche Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
11.2.5 Roche Recent Development
11.3 ORIOMICS
11.3.1 ORIOMICS Company Details
11.3.2 ORIOMICS Business Overview
11.3.3 ORIOMICS Circulating Tumour DNA (ctDNA) Testing Introduction
11.3.4 ORIOMICS Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
11.3.5 ORIOMICS Recent Development
11.4 Signatera
11.4.1 Signatera Company Details
11.4.2 Signatera Business Overview
11.4.3 Signatera Circulating Tumour DNA (ctDNA) Testing Introduction
11.4.4 Signatera Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
11.4.5 Signatera Recent Development
11.5 Illumina
11.5.1 Illumina Company Details
11.5.2 Illumina Business Overview
11.5.3 Illumina Circulating Tumour DNA (ctDNA) Testing Introduction
11.5.4 Illumina Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
11.5.5 Illumina Recent Development
11.6 Sysmex Corporation
11.6.1 Sysmex Corporation Company Details
11.6.2 Sysmex Corporation Business Overview
11.6.3 Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Introduction
11.6.4 Sysmex Corporation Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
11.6.5 Sysmex Corporation Recent Development
11.7 Bio-Rad
11.7.1 Bio-Rad Company Details
11.7.2 Bio-Rad Business Overview
11.7.3 Bio-Rad Circulating Tumour DNA (ctDNA) Testing Introduction
11.7.4 Bio-Rad Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
11.7.5 Bio-Rad Recent Development
11.8 Biocartis
11.8.1 Biocartis Company Details
11.8.2 Biocartis Business Overview
11.8.3 Biocartis Circulating Tumour DNA (ctDNA) Testing Introduction
11.8.4 Biocartis Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
11.8.5 Biocartis Recent Development
11.9 QIAGEN
11.9.1 QIAGEN Company Details
11.9.2 QIAGEN Business Overview
11.9.3 QIAGEN Circulating Tumour DNA (ctDNA) Testing Introduction
11.9.4 QIAGEN Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
11.9.5 QIAGEN Recent Development
11.10 GuardantHealth
11.10.1 GuardantHealth Company Details
11.10.2 GuardantHealth Business Overview
11.10.3 GuardantHealth Circulating Tumour DNA (ctDNA) Testing Introduction
11.10.4 GuardantHealth Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
11.10.5 GuardantHealth Recent Development
11.11 GSK plc
11.11.1 GSK plc Company Details
11.11.2 GSK plc Business Overview
11.11.3 GSK plc Circulating Tumour DNA (ctDNA) Testing Introduction
11.11.4 GSK plc Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
11.11.5 GSK plc Recent Development
11.12 AstraZeneca
11.12.1 AstraZeneca Company Details
11.12.2 AstraZeneca Business Overview
11.12.3 AstraZeneca Circulating Tumour DNA (ctDNA) Testing Introduction
11.12.4 AstraZeneca Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
11.12.5 AstraZeneca Recent Development
11.13 NeoGenomics Laboratories
11.13.1 NeoGenomics Laboratories Company Details
11.13.2 NeoGenomics Laboratories Business Overview
11.13.3 NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Introduction
11.13.4 NeoGenomics Laboratories Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
11.13.5 NeoGenomics Laboratories Recent Development
11.14 AmoyDx
11.14.1 AmoyDx Company Details
11.14.2 AmoyDx Business Overview
11.14.3 AmoyDx Circulating Tumour DNA (ctDNA) Testing Introduction
11.14.4 AmoyDx Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
11.14.5 AmoyDx Recent Development
11.15 Annoroad
11.15.1 Annoroad Company Details
11.15.2 Annoroad Business Overview
11.15.3 Annoroad Circulating Tumour DNA (ctDNA) Testing Introduction
11.15.4 Annoroad Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
11.15.5 Annoroad Recent Development
11.16 Burning Rock Biotech
11.16.1 Burning Rock Biotech Company Details
11.16.2 Burning Rock Biotech Business Overview
11.16.3 Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Introduction
11.16.4 Burning Rock Biotech Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
11.16.5 Burning Rock Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Roche
Illumina Inc
Sysmex Corporation
Bio Rad
Biocartis
Qiagen NV
GuardantHealth
GSK
Astrazeneca plc
Neogenomics Laboratories
Amoydx
Annoroad
Burning Rock Biotech
Nexomics
ORIOMICS
Signatera
List of Tables
 Table 1. Global Circulating Tumour DNA (ctDNA) Testing Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Gastric Cancer Methylation Screening
 Table 3. Key Players of Esophageal Cancer Methylation Screening
 Table 4. Key Players of Colorectal Cancer Methylation Screening
 Table 5. Key Players of Lung Cancer Methylation Screening
 Table 6. Key Players of Liver Cancer Methylation Screening
 Table 7. Key Players of Other Cancer Screening
 Table 8. Global Circulating Tumour DNA (ctDNA) Testing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 10. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2020-2025) & (US$ Million)
 Table 11. Global Circulating Tumour DNA (ctDNA) Testing Market Share by Region (2020-2025)
 Table 12. Global Circulating Tumour DNA (ctDNA) Testing Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 13. Global Circulating Tumour DNA (ctDNA) Testing Market Share by Region (2026-2031)
 Table 14. Circulating Tumour DNA (ctDNA) Testing Market Trends
 Table 15. Circulating Tumour DNA (ctDNA) Testing Market Drivers
 Table 16. Circulating Tumour DNA (ctDNA) Testing Market Challenges
 Table 17. Circulating Tumour DNA (ctDNA) Testing Market Restraints
 Table 18. Global Circulating Tumour DNA (ctDNA) Testing Revenue by Players (2020-2025) & (US$ Million)
 Table 19. Global Circulating Tumour DNA (ctDNA) Testing Market Share by Players (2020-2025)
 Table 20. Global Top Circulating Tumour DNA (ctDNA) Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumour DNA (ctDNA) Testing as of 2024)
 Table 21. Ranking of Global Top Circulating Tumour DNA (ctDNA) Testing Companies by Revenue (US$ Million) in 2024
 Table 22. Global 5 Largest Players Market Share by Circulating Tumour DNA (ctDNA) Testing Revenue (CR5 and HHI) & (2020-2025)
 Table 23. Global Key Players of Circulating Tumour DNA (ctDNA) Testing, Headquarters and Area Served
 Table 24. Global Key Players of Circulating Tumour DNA (ctDNA) Testing, Product and Application
 Table 25. Global Key Players of Circulating Tumour DNA (ctDNA) Testing, Date of Enter into This Industry
 Table 26. Mergers & Acquisitions, Expansion Plans
 Table 27. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Type (2020-2025) & (US$ Million)
 Table 28. Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Type (2020-2025)
 Table 29. Global Circulating Tumour DNA (ctDNA) Testing Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 30. Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Type (2026-2031)
 Table 31. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2020-2025) & (US$ Million)
 Table 32. Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Application (2020-2025)
 Table 33. Global Circulating Tumour DNA (ctDNA) Testing Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 34. Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Application (2026-2031)
 Table 35. North America Circulating Tumour DNA (ctDNA) Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. North America Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2020-2025) & (US$ Million)
 Table 37. North America Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Europe Circulating Tumour DNA (ctDNA) Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2020-2025) & (US$ Million)
 Table 40. Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2026-2031) & (US$ Million)
 Table 41. Asia-Pacific Circulating Tumour DNA (ctDNA) Testing Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Asia-Pacific Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2020-2025) & (US$ Million)
 Table 43. Asia-Pacific Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2026-2031) & (US$ Million)
 Table 44. Latin America Circulating Tumour DNA (ctDNA) Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Latin America Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Latin America Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 48. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2020-2025) & (US$ Million)
 Table 49. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2026-2031) & (US$ Million)
 Table 50. Nexomics Company Details
 Table 51. Nexomics Business Overview
 Table 52. Nexomics Circulating Tumour DNA (ctDNA) Testing Product
 Table 53. Nexomics Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025) & (US$ Million)
 Table 54. Nexomics Recent Development
 Table 55. Roche Company Details
 Table 56. Roche Business Overview
 Table 57. Roche Circulating Tumour DNA (ctDNA) Testing Product
 Table 58. Roche Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025) & (US$ Million)
 Table 59. Roche Recent Development
 Table 60. ORIOMICS Company Details
 Table 61. ORIOMICS Business Overview
 Table 62. ORIOMICS Circulating Tumour DNA (ctDNA) Testing Product
 Table 63. ORIOMICS Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025) & (US$ Million)
 Table 64. ORIOMICS Recent Development
 Table 65. Signatera Company Details
 Table 66. Signatera Business Overview
 Table 67. Signatera Circulating Tumour DNA (ctDNA) Testing Product
 Table 68. Signatera Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025) & (US$ Million)
 Table 69. Signatera Recent Development
 Table 70. Illumina Company Details
 Table 71. Illumina Business Overview
 Table 72. Illumina Circulating Tumour DNA (ctDNA) Testing Product
 Table 73. Illumina Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025) & (US$ Million)
 Table 74. Illumina Recent Development
 Table 75. Sysmex Corporation Company Details
 Table 76. Sysmex Corporation Business Overview
 Table 77. Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Product
 Table 78. Sysmex Corporation Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025) & (US$ Million)
 Table 79. Sysmex Corporation Recent Development
 Table 80. Bio-Rad Company Details
 Table 81. Bio-Rad Business Overview
 Table 82. Bio-Rad Circulating Tumour DNA (ctDNA) Testing Product
 Table 83. Bio-Rad Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025) & (US$ Million)
 Table 84. Bio-Rad Recent Development
 Table 85. Biocartis Company Details
 Table 86. Biocartis Business Overview
 Table 87. Biocartis Circulating Tumour DNA (ctDNA) Testing Product
 Table 88. Biocartis Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025) & (US$ Million)
 Table 89. Biocartis Recent Development
 Table 90. QIAGEN Company Details
 Table 91. QIAGEN Business Overview
 Table 92. QIAGEN Circulating Tumour DNA (ctDNA) Testing Product
 Table 93. QIAGEN Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025) & (US$ Million)
 Table 94. QIAGEN Recent Development
 Table 95. GuardantHealth Company Details
 Table 96. GuardantHealth Business Overview
 Table 97. GuardantHealth Circulating Tumour DNA (ctDNA) Testing Product
 Table 98. GuardantHealth Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025) & (US$ Million)
 Table 99. GuardantHealth Recent Development
 Table 100. GSK plc Company Details
 Table 101. GSK plc Business Overview
 Table 102. GSK plc Circulating Tumour DNA (ctDNA) Testing Product
 Table 103. GSK plc Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025) & (US$ Million)
 Table 104. GSK plc Recent Development
 Table 105. AstraZeneca Company Details
 Table 106. AstraZeneca Business Overview
 Table 107. AstraZeneca Circulating Tumour DNA (ctDNA) Testing Product
 Table 108. AstraZeneca Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025) & (US$ Million)
 Table 109. AstraZeneca Recent Development
 Table 110. NeoGenomics Laboratories Company Details
 Table 111. NeoGenomics Laboratories Business Overview
 Table 112. NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Product
 Table 113. NeoGenomics Laboratories Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025) & (US$ Million)
 Table 114. NeoGenomics Laboratories Recent Development
 Table 115. AmoyDx Company Details
 Table 116. AmoyDx Business Overview
 Table 117. AmoyDx Circulating Tumour DNA (ctDNA) Testing Product
 Table 118. AmoyDx Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025) & (US$ Million)
 Table 119. AmoyDx Recent Development
 Table 120. Annoroad Company Details
 Table 121. Annoroad Business Overview
 Table 122. Annoroad Circulating Tumour DNA (ctDNA) Testing Product
 Table 123. Annoroad Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025) & (US$ Million)
 Table 124. Annoroad Recent Development
 Table 125. Burning Rock Biotech Company Details
 Table 126. Burning Rock Biotech Business Overview
 Table 127. Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Product
 Table 128. Burning Rock Biotech Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025) & (US$ Million)
 Table 129. Burning Rock Biotech Recent Development
 Table 130. Research Programs/Design for This Report
 Table 131. Key Data Information from Secondary Sources
 Table 132. Key Data Information from Primary Sources
 Table 133. Authors List of This Report


List of Figures
 Figure 1. Circulating Tumour DNA (ctDNA) Testing Picture
 Figure 2. Global Circulating Tumour DNA (ctDNA) Testing Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Circulating Tumour DNA (ctDNA) Testing Market Share by Type: 2024 VS 2031
 Figure 4. Gastric Cancer Methylation Screening Features
 Figure 5. Esophageal Cancer Methylation Screening Features
 Figure 6. Colorectal Cancer Methylation Screening Features
 Figure 7. Lung Cancer Methylation Screening Features
 Figure 8. Liver Cancer Methylation Screening Features
 Figure 9. Other Cancer Screening Features
 Figure 10. Global Circulating Tumour DNA (ctDNA) Testing Market Size by Application (2020-2031) & (US$ Million)
 Figure 11. Global Circulating Tumour DNA (ctDNA) Testing Market Share by Application: 2024 VS 2031
 Figure 12. Hospital Case Studies
 Figure 13. Medical Center Case Studies
 Figure 14. Laboratory Case Studies
 Figure 15. Circulating Tumour DNA (ctDNA) Testing Report Years Considered
 Figure 16. Global Circulating Tumour DNA (ctDNA) Testing Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 17. Global Circulating Tumour DNA (ctDNA) Testing Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 18. Global Circulating Tumour DNA (ctDNA) Testing Market Share by Region: 2024 VS 2031
 Figure 19. Global Circulating Tumour DNA (ctDNA) Testing Market Share by Players in 2024
 Figure 20. Global Top Circulating Tumour DNA (ctDNA) Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumour DNA (ctDNA) Testing as of 2024)
 Figure 21. The Top 10 and 5 Players Market Share by Circulating Tumour DNA (ctDNA) Testing Revenue in 2024
 Figure 22. North America Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. North America Circulating Tumour DNA (ctDNA) Testing Market Share by Country (2020-2031)
 Figure 24. United States Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Canada Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Europe Circulating Tumour DNA (ctDNA) Testing Market Share by Country (2020-2031)
 Figure 28. Germany Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. France Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. U.K. Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Italy Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Russia Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Nordic Countries Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Asia-Pacific Circulating Tumour DNA (ctDNA) Testing Market Share by Region (2020-2031)
 Figure 36. China Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Japan Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. South Korea Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Southeast Asia Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. India Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Australia Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Latin America Circulating Tumour DNA (ctDNA) Testing Market Share by Country (2020-2031)
 Figure 44. Mexico Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Brazil Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Share by Country (2020-2031)
 Figure 48. Turkey Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Saudi Arabia Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. UAE Circulating Tumour DNA (ctDNA) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 51. Nexomics Revenue Growth Rate in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
 Figure 52. Roche Revenue Growth Rate in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
 Figure 53. ORIOMICS Revenue Growth Rate in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
 Figure 54. Signatera Revenue Growth Rate in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
 Figure 55. Illumina Revenue Growth Rate in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
 Figure 56. Sysmex Corporation Revenue Growth Rate in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
 Figure 57. Bio-Rad Revenue Growth Rate in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
 Figure 58. Biocartis Revenue Growth Rate in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
 Figure 59. QIAGEN Revenue Growth Rate in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
 Figure 60. GuardantHealth Revenue Growth Rate in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
 Figure 61. GSK plc Revenue Growth Rate in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
 Figure 62. AstraZeneca Revenue Growth Rate in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
 Figure 63. NeoGenomics Laboratories Revenue Growth Rate in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
 Figure 64. AmoyDx Revenue Growth Rate in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
 Figure 65. Annoroad Revenue Growth Rate in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
 Figure 66. Burning Rock Biotech Revenue Growth Rate in Circulating Tumour DNA (ctDNA) Testing Business (2020-2025)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Global Circulating Tumor DNA Diagnostics Market Research Report 2025
Global Cell free Tumor DNA Detection Market Research Report 2025
Global ctDNA Detection Market Research Report 2025
Global ctDNA Detection Kit Market Research Report 2024
Global Cell Free Circulating Tumor DNA ctDNA Market Research Report 2024
ctDNA Methylation Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Circulating Tumor DNA Test Kit Market Research Report 2024
Global Circulating Tumor Cells Market Research Report 2025
Global Liquid Biopsy Products Market Insights Forecast to 2030
Global Circulating Tumor Cell CTC Detection Market Research Report 2024
Global Circulating Tumor Cells CTCs Detectors Market Research Report 2024
Global CTC Detection Market Research Report 2025
Circulating Tumor Cell CTC Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Circulating Tumor Cells and Cancer Stem Cells Market Research Report 2024
Global Circulating Tumor Cell CTC Detector Market Research Report 2024
Global Circulating Tumor Cells CTCs and Cancer Stem Cells CSCs Market Insights Forecast to 2030
Global Circulating Tumor Cell Diagnostics Market Insights Forecast to 2030
Global Circulating Tumor Cell Detection System Market Research Report 2024
Global Cell Free DNA cfDNA Testing Market Research Report 2024
Global Free Circulating Tumor Cell Detection Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions